Duration of Treatment for Osteoporosis.

Duration of treatment for osteoporosis.

Reumatismo. 2013; 65(1): 22-35
Idolazzi L, Fassio A, Gatti D, Tamanini S, Viapiana O, Rossini M, Adami S

Many treatments for postmenopausal osteoporosis with proven efficacy in lowering fracture risk had become available since many years now. In the last few years the issue about treatment duration has become a matter of importance. In this paper the pivotal trials for alendronate, risedronate, zoledronate and other anti reabsorptive drugs such as denosumab are revised with particular attention to the extension studies aimed to verify the effect of drug discontinuation. The results of the review highlight differences among the available drugs and the practical clinical consequences also in terms of cost-effectiveness. HubMed – drug


Digital eye drop instillation – A novel method.

Aust Fam Physician. 2013 Apr; 42(4): 201-2
Krilis M, Coroneo M

Local drug treatment in ophthalmology by the use of eye drops has meant that potent drugs can be used, thereby minimising systemic side effects. While seemingly a simple task, insertion of eye drops can be problematic for certain patients and in particular circumstances.To describe a novel method for the administration of eye drops, which overcomes the main problems of conventional eye drop administration.Our pragmatic method of eye drop application provides a way of improving compliance and reducing ocular surface injury. Our experience to date is that the technique is at least as safe as that used for insertion of contact lenses from an infection risk perspective. HubMed – drug


Microbiological characteristics of acute prostatitis after transrectal prostate biopsy.

Korean J Urol. 2013 Feb; 54(2): 117-22
Bang JH, Choe HS, Lee DS, Lee SJ, Cho YH

We aimed to identify microbiological characteristics in patients with acute prostatitis after transrectal prostate biopsy to provide guidance in the review of prevention and treatment protocols.A retrospective analysis of medical records was performed in 1,814 cases who underwent prostate biopsy at Seoul St. Mary’s Hospital and St. Vincent’s Hospital over a 5 year period from 2006 to 2011. Cases in which acute prostatitis occurred within 7 days after the biopsy were investigated. Before starting treatment with antibiotics, sample collections were done for culture of urine and blood. Culture and drug susceptibility was identified by use of a method established by the Clinical and Laboratory Standards Institute.A total of 1,814 biopsy procedures were performed in 1,541 patients. For 1,246 patients, the procedure was the first biopsy, whereas for 295 patients it was a repeat biopsy. Twenty-one patients (1.36%) were identified as having acute bacterial prostatitis after the biopsy. Fifteen patients (1.2%) had acute prostatitis after the first biopsy, and 6 patients (2.03%) experienced acute prostatitis after a repeat biopsy. Even though the incidence of acute bacterial prostatitis was higher after repeat biopsy than that after the first biopsy, there was no statistically significant intergroup difference in terms of incidence (?(2)=1.223, p=0.269). When the collected urine and blood samples were cultured, Escherichia coli was found in samples from 15 patients (71.4%), Klebsiella pneumoniae in 3 patients (14.3%), Enterobacter intermedius in 1 patient (4.8%), E. aerogenes in 1 patient (4.8%), and Pseudomonas aeruginosa in 1 patient (4.8%). A fluoroquinolone-resistant strain was confirmed in 5 cases (23.8%) in total. Three cases of E. coli and 1 case of Klebsiella had extended-spectrum ?-lactamase activity.Empirical treatment of acute prostatitis should be done with consideration of geographical prevalence and drug resistance. This study will provide meaningful information for the management of acute prostatitis after transrectal prostate biopsy. HubMed – drug



Nollie Robinson Program Director/ CEO A Road to Recovery Treatment center – Nollie Robinson Program Director/ CEO A Road to Recovery Treatment center. Hi my name is Nollie Robinson and I am the executive director and CEO of A Road to…